Loading news...
Shares of CONMED Corporation (NYSE: CNMD - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating
CONMED (NYSE: CNMD) reported fourth-quarter fiscal 2025 sales of $373.2 million, representing a 7.9% year-over-year increase as reported and 7.1% growth in constant currency, as management emphasized continued progress in orthopedics and improved supply conditions. For the full year, sales were $1.375 billion, up 5.2% as reported and 5.1% in constant currency. President and CEO Pat
CNMD posts strong fourth-quarter 2025 results with EPS and revenue beat, driven by surgical growth and improved gross margin.
Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CONMED Corporation (CNMD) Q4 2025 Earnings Call Transcript
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency. Domestic revenue increased 1.4% year-over-year. International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency. Diluted net earnings per share (GAAP) were $0.54, compared to dilute.
CONMED Corporation (CNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the departure of Todd Garner from his role as Chief Financial Officer effective March 15, 2026. To ensure a smooth and orderly transition, Mr. Garner will remain with the Company in an advisory capacity through November 2, 2026. CONMED has initiated a comprehensive search process, supported by a leading executive search firm, to identify its next Chief Financial Officer. “On behalf of our Board and leadership team, I.
CONMED Corporation (NYSE: CNMD - Get Free Report) has earned an average rating of "Reduce" from the eight analysts that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating on the company. The average
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Patrick J. Beyer, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT (6:00 p.m. ET) on Monday, January 12, 2026 in San Francisco, CA. A live audio webcast of the presentation will be accessible through the “Investors” section of the Company's website at www.conmed.com and.
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the fourth quarter 2025 after the market close on Wednesday, January 28, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed.
CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CNMD is set to exit its gastroenterology portfolio to streamline its focus on higher-growth surgical platforms and boost long-term margins.
CONMED Corporation (NYSE: CNMD - Get Free Report) shares reached a new 52-week low on Saturday. The stock traded as low as $38.95 and last traded at $40.1640, with a volume of 1285341 shares. The stock had previously closed at $44.24. Analyst Ratings Changes Several equities analysts recently issued reports on the stock. JPMorgan Chase
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows CONMED to fully align operations and resources within its core markets—minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair. “Today's announcement reflects a positive step in our strategic portfolio review and o.
CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins.